ArticleCancers2021

Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features.

Antonio Passaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.